**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 35344**

**Manuscript Type: META-ANALYSIS**

**Short-term clinical outcomes of laparoscopic *vs* open rectal excision   
for rectal cancer: A systematic review and meta-analysis**

Martínez-Pérez A *et al.* Laparoscopic *vs* open surgery for rectal cancer

Aleix Martínez-Pérez,Maria Clotilde Carra, Francesco Brunetti, Nicola de’Angelis

**Aleix Martínez-Pérez,Francesco Brunetti, Nicola de’Angelis,** Department of Digestive, Hepatobiliary Surgery and Liver Transplantation, Henri Mondor University Hospital, AP-HP, Université Paris Est - UPEC, 94010 Créteil, France

**Aleix Martínez-Pérez,** Department of General and Digestive Surgery, Hospital Universitario Doctor Peset, 46017 Valencia, Spain

**Maria Clotilde Carra,** Rothschild Hospital, AP-HP, Université Paris VII, 75012 Paris, France

**ORCID number:** Aleix Martínez-Pérez (0000-0003-0601-932X); Maria Clotilde Carra (0000-0002-5717-3274); Francesco Brunetti (0000-0003-1686-691X); Nicola de’Angelis (0000-0002-1211-4916).

**Author contributions:** Martínez-Pérez A and de’Angelis N contributed to conception and design of the study, and drafted the manuscript; Martínez-Pérez A, Carra MC and de’Angelis N contributed to data acquisition, data analysis and interpretation; Brunetti F critically revised the article; all authors approved the final version.

**Conflict-of-interest statement:** The authors deny any conflict of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Nicola de’Angelis, MD, PhD, Assistant Professor,** Department of Digestive, Hepato-biliary Surgery and Liver Transplantation, Henri Mondor University Hospital, AP-HP, Université Paris Est - UPEC, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France. nicola.deangelis@aphp.fr

**Telephone:** +33-1-49812348

**Fax:** +33-1-49812432

**Received:** july 10, 2017

**Peer-review started:** july 12, 2017

**First decision:** August 30, 2017

**Revised:** September 9, 2017

**Accepted:** September 20, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To review evidence on the short-term clinical outcomes of laparoscopic (LRR) *vs* open rectal resection (ORR) for rectal cancer.

***METHODS***

A systematic literature search was performed using Cochrane Central Register, MEDLINE, EMBASE, Scopus, OpenGrey and ClinicalTrials.gov register for randomized clinical trials (RCTs) comparing LRR vs ORR for rectal cancer and reporting short-term clinical outcomes. Articles published in English from January 1, 1995 to June, 30 2016 that met the selection criteria were retrieved and reviewed. The Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statements checklist for reporting a systematic review was followed. Random-effect models were used to estimate mean differences and risk ratios.The robustness and heterogeneity of the results were explored by performing sensitivity analyses. The pooled effect was considered significant when *p* < 0.05.

***RESULTS***

Overall,14 RCTs were included. No differences were found in postoperative mortality (*p* = 0.19) and morbidity (*p* = 0.75) rates. The mean operative time was 36.67 min longer (95%CI: 27.22-46.11, *p* < 0.00001), the mean estimated blood loss was 88.80 ml lower (95%CI: -117.25 to -60.34, *p* < 0.00001), and the mean incision length was 11.17 cm smaller (95%CI: -13.88 to -8.47, *p* < 0.00001) for LRR than ORR. These results were confirmed by sensitivity analyses that focused on the four major RCTs. The mean length of hospital stay was 1.71 d shorter (95%CI: -2.84 to -0.58, *p* < 0.003) for LRR than ORR. Similarly, bowel recovery (*i.e*., day of the first bowel movement) was 0.68 d shorter (95%CI: -1.00 to -0.36, *p* < 0.00001) for LRR. The sensitivity analysis did not confirm a significant difference between LRR and ORR for these latter two parameters. The overall quality of the evidence was rated as high.

***CONCLUSION***

LRR is associated with lesser blood loss, smaller incision length, and longer operative times compared to ORR. No differences are observed for postoperative morbidity and mortality.

**Key words:** Laparoscopic rectal resection; Open rectal resection; Laparoscopy; Rectal cancer; Postoperative morbidity; Short-term outcomes; Systematic review; Meta-analysis

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** There is no consensus on which technique, between laparoscopic rectal resection (LRR) and open rectal resection (ORR), is more beneficial for the patient. A systematic review and meta-analysis exclusively based on randomized clinical trials comparing LRR *vs* ORR has been performed. The pooled analyses focused on the evaluation and comparison of short-term clinical outcomes and showed that postoperative morbidity and mortality are similar between the two surgical approaches. However, LRR is associated with lesser blood loss and smaller incision length, which may represent clinical advantages for the patient.

Martínez-Pérez A,Carra MC, Brunetti F, de’Angelis N. Short-term clinical outcomes of laparoscopic *vs* open rectal excision for rectal cancer: A systematic review and meta-analysis. *World J Gastroenterol* 2017; In press

**INTRODUCTION**

The oncologic principles for the curative treatment of rectal cancer imply the complete removal of the tumor and the mesorectum[1]. In locally advanced rectal cancers, oncologic outcomes can be improved by tailored multi-disciplinary approaches that combine surgery with neoadjuvant chemoradiation therapy[2].

Laparoscopy is currently useful for the resection of rectal cancer. The results of multi-centric randomized clinical trials (RCTs) have shown that laparoscopic rectal resection (LRR) was associated with more favorable short-term outcomes compared to open rectal resection (ORR)[3,4]. Specifically, the COLOR II trial showed statistically significant differences in favor of LRR in terms of blood loss, bowel recovery, and the length of hospital stay, with no differences between the two approaches in postoperative morbidity and mortality[3]. The COREAN study achieved similar results, and showed less postoperative pain and better physical and intestinal recovery after LRR[4].In the more recent ACOSOG Z6051 and ALaCaRT trials, LRRwas associated with longer operative times, less blood loss, and faster post-surgery bowel movements [ACOSOG] or time to flatus compared to ORR [ALACART], despite no observed group differences in the length of hospital stay[5,6]. Two recent meta-analyses had compared the short-term clinical results of LRR versus ORR based on pooled actualized data from the relevant literature on rectal cancer. They shown, among others advantages, a significant lesser postoperative morbidity[7,8] and mortality[7] for patients undergoing LRR over those who received ORR[7,8]. However, they considered both RCTs and non-RCTs, a critical factor that dampens the strength of the results due to the quality of the selected studies and the risk of bias. Furthermore, the results of a recent RCTs-based meta-analysis focusing exclusively on the pathologic outcomes of LRR vs ORR reignited the debate regarding the oncological safety of laparoscopy for rectal cancer in terms of quality of mesorectal resection[9]. Thus, while waiting for the long-term data of the ongoing RCTs, we conducted a systematic review and meta-analysis on RCTs only to evaluate the best level of evidence available so far on the short-term clinical outcomes of laparoscopic versus open rectal resections in patients with rectal cancer.

**Materials and methods**

***Literature search***

A literature search was performed on the following online databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (through PubMed), EMBASE, and Scopus. To increase the probability of identifying all relevant articles, a specific research equation was formulated for each database, using the following keywords and/or MESH terms: rectal/colorectal cancer/carcinoma, treatment, therapy, management, surgery, laparoscopy/laparoscopic surgery, open surgery/laparotomy, and randomized trial/trial. Moreover, the reference lists of the eligible studies and relevant review articles were crosschecked to identify additional pertinent studies. Grey literature was explored on the OpenGrey database and the ClinicalTrials.gov registry was also searched to look for any ongoing RCT whose results might be published in the near future. Articles published in English from January 1, 1995 to June, 30 2016 that met the selection criteria were retrieved and reviewed.

***Study design***

The methodological approach for this systematic review included the development of selection criteria, the definition of search strategies, the assessment of study quality, and an abstraction of relevant data. The Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statements checklist for reporting a systematic review was followed[10].

The eligibility and selection criteria were defined before the data search was initiated to ensure the proper identification of all studies that were eligible to be included in the systematic review and meta-analysis. Only RCTs that compared LRR and ORR and reported at least one of the outcomes of interest were retrieved and analyzed. No trial duration limitation was applied. Non-randomized studies, retrospective studies, case reports, review articles, commentaries, and conference abstracts were not considered in the systematic review. Studies that reported the results of surgical teams during their learning curve in laparoscopic rectal resection were excluded.

By applying the PICO framework, the study selection criteria were as follows:

**Participants:** Adult patients with histologically confirmed rectal cancer that required a surgical resection.

**Interventions:** Laparoscopic (including laparoscopic-assisted) or open rectal resection. Studies were included independently of the surgical technique (*e.g.,* abdominoperineal resection or anterior resection) and the performance of a primary anastomosis.

**Comparisons:** LRR *vs* ORR.

**Outcome measures:** include short-term surgical and clinical outcomes that were divided into: (1) Intraoperative outcomes: mean operative time (min), intraoperative morbidity rate (%), mean estimated blood loss (ml), mean incision length (cm), ureter injury rate (%), gastrointestinal injury rate (%). And (2) postoperative outcomes: postoperative morbidity rate (%), postoperative mortality rate (%), mean length of hospital stay (days), anastomotic leak rate (%), reoperation rate (%), ileus rate (%), time to bowel recovery (day of first bowel movement in days), wound infection rate (%), chest infection rate (%), urinary infection rate (%).

***Data extraction***

Initially, titles and abstracts of the retrieved studies were independently and blindly screened for relevance by two reviewers (AM-P and NdeA) according to the 2010 CONSORT Statement for RCTs ([www.consort-statement.org](http://www.consort-statement.org)). To enhance sensitivity, records were removed only if both reviewers excluded the record at the initial screening level. Subsequently, both reviewers performed a full-text analysis of the selected articles.

***Risk of bias***

Both reviewers independently assessed the risk of bias using the Cochrane “Risk of Bias” tool, as described in the Cochrane Handbook for Systematic Reviews of Interventions[11]. Additionally, the Grading of Recommendations Assessment Development and Evaluation (GRADE) system was used to grade the “body of evidence” that emerged from the review[12]. All disagreements between the two reviewers in the selection and evaluation processes were resolved by discussion with a third reviewer (FB).

***Statistical analysis***

Data from the included studies were processed using qualitative and quantitative analyses. For binary outcome data, the relative risk (RR) and 95% confidence intervals (CI) were estimated using the Mantel–Haenszel method. For continuous data, the mean differences (MD) and 95%CIs were estimated using inverse variance weighting. Outcome measures (mean and median values, standard deviations, interquartile ranges) were extracted for each surgical treatment. If necessary and possible, outcome variables were calculated based on the data available in the individual studies. If the standard error (SE) was provided instead of a standard deviation (SD), the SD was calculated based on the sample size (SE = SD/variables were calculated based on the data available in the individual studies. Whether neither mean or SD values were reported, they were estimated from the median, ranges, interquartile ranges (IQR) or *p* values[13,14]. Heterogeneity was assessed by the I2 statistic[11,15,16]. I² values of 25%, 50%, and 75% were considered as low, moderate, and high, respectively[11,16].

The pooled estimates of the mean differences were calculated using random effects models to consider potential inter-study heterogeneity and to adopt a more conservative approach. Then, the robustness of the results and the potential sources of heterogeneity were explored by performing sensitivity analyses (*e.g.*, subgroup analyses; comparison using a fixed-effects model). The pooled effect was considered significant if *p* < 0.05. The meta-analysis was performed using Review Manager (RevMan, version 5.3, Cochrane Collaboration, Copenhagen, Denmark).

**RESULTS**

***Study selection***

Overall, the combined search identified 6205 articles, of which 5836 were rejected based upon the title and abstract evaluation. The remaining 369 articles underwent full-text evaluation; 355 were excluded because they were not RCTs, presented duplicate data of other RCTs included in the systematic review, did not report the outcomes of interest, or presented the results of laparoscopic rectal resections during the surgeon’s learning curve. No additional study was identified through the manual search, reference lists crosschecks, grey literature or on ClinicalTrials.gov. Finally, 14 eligible articles were found and were included in the qualitative and quantitative analyses. The flowchart of the literature search and the study selection process is shown in Figure 1.

The 14 selected studies were published between 2003 and 2015. They included patients who had surgery between September 1993 and November 2014. Nine studies were performed in single centers[17-25], whereas 5 were multi-centric studies[3-6,26]. Overall, these studies analyzed a total of 4132 patients who underwent either open (*n* = 1819) or laparoscopic (*n* = 2313) rectal resections. In this latter group, 13.8% of patients (range: 0%-33.9%) required a conversion from laparoscopy to open surgery. Table 1 displays the baseline characteristics of patients who underwent LRR or ORR.

***Intraoperative outcomes***

Mean operative time was significantly longer, the estimated blood loss and the mean incision length significantly lower for LRR than ORR (Figure 2a-c). Conversely, no significant differences were observed for ureteric or gastrointestinal injury rates, or for overall intraoperative morbidity (Table 2).

***Postoperative outcomes***

The mean length of hospital stay was reported in 12 studies[3-6,17-23,26]. The overall MD was -1.71 d (95%CI: -2.84 to -0.58, *p* < 0.003) in favor of laparoscopy, with a high heterogeneity (*I2*= 90%). Bowel recovery, described as the day of the first bowel movement, was reported in 9 studies[3,5,6,17,20-24,26]. The overall MD was -0.68 d (95%CI: -1.00 to -0.36, *p* < 0.00001) in favor of laparoscopy, with a high heterogeneity (*I*2 = 79%) (Figure 2d and e). Anastomotic leak[3-5,17,19-21,23,24], postoperative morbidity[3-5,17-23,25,26], and mortality[3-6,17-24] rates showed no significant differences between LRR and ORR (Table 2).

***Sensitivity analysis***

Sensitivity analyses performed to test the impact of using fixed-effect models showed the same results for all variables that for random effect models. Subgroup analysis was also performed by including the four largest multi-centric trials only (namely, the ACOSOG Z6051, AlaCaRT, COLOR II, and COREAN trials[3-6]). These 4 studies comprised 2319 patients (56.2% of the total). Although being a high-populated multi-centric RCT, the UK MRC-CLASICC trial[26] was not included in the sensitivity analysis because it was conducted in the early years of laparoscopic surgery and included both colon and rectal cancers. The estimated blood loss and the length of incision were significantly lower with an operative time that was significantly higher for LRR compared with ORR, but the heterogeneity remained high. For the postoperative variables, the length of hospital stay and bowel recovery did not reach statistical significance in favor of LRR. Heterogeneity decreased to moderate for length of hospital stay and remained high for bowel recovery (Table 2).

***Study quality assessment***

The assessment of study quality and the risk of bias, according to the Cochrane Collaboration tool for RCTs, are shown in Supplemental Table 1. Overall, 10 studies were classified as a low risk of bias[3-6,17,19-22,26], 1 at an unknown risk of bias[24] and 3 studies at a high risk of bias[18,23,25]. By applying the GRADE system, the overall quality of the evidence was rated as high.

**DISCUSSION**

This systematic review and meta-analysis focuses on the short-term clinical outcomes of laparoscopic versus open resection for the treatment of rectal cancer and shows that there are no differences in postoperative morbidity and mortality between the two approaches. However, LRR is associated with significantly longer operative time, lesser blood loss, and smaller incision than ORR. The length of hospital stay and the time to bowel recovery are shorter for LRR in the overall analysis but are not significantly different when considering the major RCTs only.

Previous meta-analyses have reported contrasting results about the benefits associated with the use of laparoscopy for rectal cancer instead of conventional open surgery. In 2013, Arezzo *et al*[27] analyzed 8 RCTs and 15 non-RCTs and showed a significantly lower postoperative mortality and morbidity in LRR than ORR. A more recent meta-analysis by Zhao *et al*[28] and the latest Cochrane review[29], both based on RCTs only, showed no differences in overall morbidity and mortality. However, they found better outcomes for laparoscopy in terms of blood loss, length of hospital stay, wound infection, and bowel recovery compared to open surgery. Noticeably, the above-mentioned meta-analyses were performed before the two largest and most recent RCTs being published, namely the ACOSOG Z6501 and ALaCaRT trials[5,6], which did not confirm the non-inferiority of laparoscopy and questioned the oncological safety of laparoscopy for rectal cancer. Indeed, the topic remains highly debated. Two recent meta-analyses published by Chen *et al*[8] and by Zheng *et al*[7] were performed to assess the outcomes of laparoscopy *vs* open surgery by including data from RCTs and non-RCTs. The study by Chen *et al*[8] demonstrated longer operative time, lesser blood loss, lesser overall complications, faster bowel recovery, shorter hospitalization, and major distal resection margin for laparoscopic surgery than open surgery[8]. However, there was found a considerable and arbitrary lack of data from the most populated RCTs[3-6] (which represented more than 50% of the patients included) for all the short-term variables analyzed, such as distance of distal resection margin[3,4,6], CRM involvement[5], lymph node harvest[3], operative time[3,4,6], hospital stay[4,6], and estimated blood loss[3,4,6]. Similarly, the meta-analysis by Zheng *et al*[7] included 38 studies and 13,408 patients, but only less than a third of patients (3978, 29.7%) were treated in RCTs. Moreover, the 32.9% of the included patients (4405 patients) were coming from a unique multi-centric observational study involving 72 Spanish hospitals[30]. Despite the eager of pooling data to gain power and answer the hot question about the advantages of laparoscopic rectal resection, caution should be paid when interpreting meta-analytic results. Contrasting result may be generated by using different statistical models, or when pooling together RCTs with non-RCTs. In general, the choice of the effect model should be assessed prior to start the data analysis and based on the researcher’s understanding of whether or not all the included studies share a common treatment effect. For surgical literature, a random-effect model seems to be more appropriate than a fixed-effect[31,32] due to the nature of the data retrieved from studies performed by researchers operating independently. Deciding between the models after performing the analysis or based upon the level of heterogeneity found (*e.g.*, whether the *I2*is higher than 40%[29] or 50%[7,8,27] or reaches significance[33]) is strongly discouraged[31,32]. Most importantly, the quality of a meta-analysis is strictly dependent on the quality of the original studies included and robustness of the findings should be tested by sensitivity analyses.

The present systematic review and meta-analysis aimed to analyze the best level of evidence available for LRR *vs* ORR, thus only high-quality RCTs were included. By applying a strict methodology, the present findings confer fewer advantages to LRR over ORR, especially when only the largest multi-centric RCTs were considered, when compared to the results of previous meta-analyses.

The main intra-operative benefit of LRR, confirmed by both the pooled data analysis and the sensitivity analysis, is a lower blood loss. This might justify the use of laparoscopy for rectal cancer resections despite longer operative times. Indeed, the amount of blood loss has been shown to be an independent predictor of adverse surgical outcomes, such as intra- and postoperative complications, cancer recurrence, and poorer survival[34,35]. Although the reasons why intraoperative blood loss would be associated with morbidity and poor survival remain unclear, some evidence supports that blood loss triggers stress and immune reactions, which may lead to an increased susceptibility of infections and cancer recurrence. Thus, minimizing blood loss, and the consequent risk of blood transfusion by meticulous and gentle dissections in the anatomical planes, may contribute to better outcomes of oncological surgery. However, it remains to be assess whether the difference observed between the two surgical approaches (*i.e*., 88.80 ml) is clinically relevant, and may potentially impact on the postoperative and long-term outcomes.

Other markers of surgical quality are the postoperative complication rates and the time to bowel recovery. Based on the pooled data analyses from the major RCTs[3-6], laparoscopy was not associated with a significantly different incidence of postoperative complications, time to bowel recovery or hospital stay compared to open surgery. Concerning bowel recovery, it can be measured with multiple clinical variables, such as the time to the first flatus, the time to a liquid or solid diet, or the time to the first bowel movement. Globally, bowel recovery was not significantly different between LRR and ORR but it must be noted that benefits in at least one of the recovery variables considered (*e.g*., time to flatus or time to regular diet) were found in all RCTs. Thus, caution should be paid before drawing definitive conclusions; differences among studies did not allow pooling data for all variables (*e.g*., the COREAN study[4] expressed bowel recovery in hours rather than days and could not be included in the meta-analysis), except for to the time to first bowel movement. Despite the non-significant results in the sensitivity analysis, bowel recovery is probably faster after LRR than ORR, but further studies are needed to confirm this finding.

The evidence emerging from this systematic review and meta-analysis can be considered of high quality since it is based exclusively upon RCTs[36], most of which with low risk of bias. However, some limitations must be acknowledged. The pooled data analyses showed high degrees of heterogeneity; this may be linked to multiple factors, such as different sample size (*e.g*., some studies presented less than 100 patients per group[17,18,20-23,25]), different tumor characteristics (*e.g*., only upper[21] or lower rectal cancer[22,25]), and different study designs (*e.g*., non-inferiority study) or protocols. For instance, neoadjuvant treatments were not performed in all studies, and therapies were not standardized. It has been hypothesized that major pathologic responses might translate into greater postoperative morbidities because of the effects of neoadjuvant chemoradiation therapy on pelvic tissues[37]. To date, only a few studies have addressed the influence of the pathologic response to neoadjuvant chemoradiation therapy on intraoperative and short-term morbidity, with contrasting results[37-40], but its impacts could neither be confirmed nor ruled out in this meta-analysis. Finally, the results of this meta-analysis cannot be generalized to the application of LRR and ORR for all types of rectal cancer. Indeed, T4 rectal cancers were excluded from most of the studies[3,4,6,17,19,22,23]. Thus, the outcomes of laparoscopy for this specific subset of tumors cannot be assumed, although a recent propensity score-matched study showed that LRR also achieved similar outcomes to ORR in pT4 rectal cancer patients[41].

The short-term benefits of laparoscopy must be counterbalanced with its safety. Indeed, uncertainty persists concerning the oncological appropriateness of laparoscopy for rectal cancer. A recent meta-analysis[9] focused on the pathologic outcomes of LRR versus ORR and showed that LRR was associated with a significantly higher rate of non-complete mesorectal excision compared with ORR, which represents a critical issue on the choice of the surgical approach. Innovative techniques, such as transanal-TME and robotics, are receiving worldwide attention in the latest years and they may represent a valuable alternative to laparoscopy, especially if they are proved to be oncologically safe, clinically advantageous for the patient, and maybe less challenging for the surgeon[42-45]. Nevertheless, data on the long-term outcomes of the ongoing RCTs are pending and they may be crucial in the definitive assessment of the role of laparoscopy in rectal cancer resection.

In conclusion, LRR and ORR show similar rates of intra- and postoperative complications, as well as morbidity and mortality. However, LRR is associated with a significantly higher operative time, lesser blood loss, and smaller incision length than ORR.

**Article Highlights**

***Research background***

Laparoscopy is widely used for the resection of rectal cancer. The associated short-term benefits for the patient (*e.g.,* faster recovery) have been highlighted in several studies, but with contrasting results. We conducted a systematic review and meta-analysis by selecting only randomized clinical trials (RCTs) that evaluated the short-term clinical outcomes of laparoscopic rectal resection (LRR) *vs* open rectal resection, (ORR) in patients with rectal cancer.

***Research motivation***

The short-term advantages of laparoscopic rectal resection remain under debate due to controversial results, especially when analyzing the most recent RCTs. Pooled data analyses of the available literature represents the best way to summarize the current evidence and support the developed and widespread of the most advantageous surgical approach.

***Research objectives***

The main objective of the present systematic review and meta-analysis was to analyze the current literature of RCTs on the surgical treatment for rectal cancer to compare the short-term outcomes of laparoscopy *vs* open surgery. The analysis of the literature has also highlighted the level of evidence and risk of bias inherent in the available studies, which should be used to design future research on the treatment of rectal cancer.

***Research methods***

This is a systematic literature review and meta-analysis that was conducted by following the guidelines of the Cochrane Collaboration as well as the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statements checklist. Literature search was performed on different databases for articles published in English from January 1, 1995 to June, 30 2016. Random-effect models were used to estimate mean differences and risk ratios between LRR and ORR.The robustness and heterogeneity of the results were explored by performing sensitivity analyses.

***Research results***

Overall,14 RCTs were analyzed. The mean operative time was longer for LRR than ORR, whereas the mean estimated blood loss and the mean incision length were lower for LRR than ORR. No differences between the two surgical approaches were found in postoperative mortality, morbidity, length of hospital stay, and time to bowel recovery. Although the overall quality of evidence was judged as high, not all the studies evaluated the same parameters. Thus, future research should use standardized definitions of postoperative outcomes in order to increase comparability and decrease heterogeneity among studies.

***Research conclusions***

LRR is associated with lesser blood loss, smaller incision length, and longer operative times compared to ORR. No differences are observed for postoperative morbidity and mortality. The short-term advantages of laparoscopic rectal resection are mainly represented by a significantly lower intraoperative blood loss and better cosmetic results compared to open surgery. Laparoscopic rectal resection is associated with the short-term outcomes of lower blood loss and smaller incision length compared to open surgery. The overall level of evidence supporting these findings is high. Laparoscopy is largely used for rectal cancer treatment and it is associated with favorable short-term outcomes. Not all short-term advantages of LRR over ORR, acknowledged in previous studies, have been confirmed by the present pooled data analyses. Laparoscopy is associated with favorable short-term outcomes and it can be used for patients with rectal cancer.

***Research perspectives***

Further studies should evaluate alternative minimally-invasive surgical techniques (*e.g.,* transanal TME or Robotics) and compare them with laparoscopy. Examining the outcomes of innovative and minimally-invasive surgical techniques, namely transanal TME or Robotics, applicable in the treatment of rectal cancer.

**REFERENCES**

1 **Heald RJ**, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. *Lancet* 1986; **1**: 1479-1482 [PMID: 2425199]

2 **Lee M**, Gibbs P, Wong R. Multidisciplinary Management of Locally Advanced Rectal Cancer--An Evolving Landscape? *Clin Colorectal Cancer* 2015; **14**: 251-261 [PMID: 26210575 DOI: 10.1016/j.clcc.2015.06.002]

3 **van der Pas MH**, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC, Bonjer HJ; COlorectal cancer Laparoscopic or Open Resection II (COLOR II) Study Group. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *Lancet Oncol* 2013; **14**: 210-218 [PMID: 23395398 DOI: 10.1016/S1470-2045(13)70016-0]

4 **Kang SB**, Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, Lim SB, Lee TG, Kim DY, Kim JS, Chang HJ, Lee HS, Kim SY, Jung KH, Hong YS, Kim JH, Sohn DK, Kim DH, Oh JH. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. *Lancet Oncol* 2010; **11**: 637-645 [PMID: 20610322 DOI: 10.1016/S1470-2045(10)70131-5]

5 **Fleshman J**, Branda M, Sargent DJ, Boller AM, George V, Abbas M, Peters WR Jr, Maun D, Chang G, Herline A, Fichera A, Mutch M, Wexner S, Whiteford M, Marks J, Birnbaum E, Margolin D, Larson D, Marcello P, Posner M, Read T, Monson J, Wren SM, Pisters PW, Nelson H. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. *JAMA* 2015; **314**: 1346-1355 [PMID: 26441179 DOI: 10.1001/jama.2015.10529]

6 **Stevenson AR**, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ, Davies L, Wilson K, Hague W, Simes J; ALaCaRT Investigators. Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial. *JAMA* 2015; **314**: 1356-1363 [PMID: 26441180 DOI: 10.1001/jama.2015.12009]

7 **Zheng J**, Feng X, Yang Z, Hu W, Luo Y, Li Y. The comprehensive therapeutic effects of rectal surgery are better in laparoscopy: a systematic review and meta-analysis. *Oncotarget* 2017; **8**: 12717-12729 [PMID: 28038460 DOI: 10.18632/oncotarget.14215]

8 **Chen K**, Cao G, Chen B, Wang M, Xu X, Cai W, Xu Y, Xiong M. Laparoscopic versus open surgery for rectal cancer: A meta-analysis of classic randomized controlled trials and high-quality Nonrandomized Studies in the last 5 years. *Int J Surg* 2017; **39**: 1-10 [PMID: 28087370 DOI: 10.1016/j.ijsu.2016.12.123]

9 **Martínez-Pérez A**, Carra MC, Brunetti F, de'Angelis N. Pathologic Outcomes of Laparoscopic vs Open Mesorectal Excision for Rectal Cancer: A Systematic Review and Meta-analysis. *JAMA Surg* 2017; **152**: e165665 [PMID: 28196217 DOI: 10.1001/jamasurg.2016.5665]

10 **Moher D**, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010; **8**: 336-341 [PMID: 20171303 DOI: 10.1016/j.ijsu.2010.02.007]

11 **Higgins JP**, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; **343**: d5928 [PMID: 22008217 DOI: 10.1136/bmj.d5928]

12 **Guyatt GH**, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; **336**: 924-926 [PMID: 18436948 DOI: 10.1136/bmj.39489.470347.AD]

13 **Hozo SP**, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* 2005; **5**: 13 [PMID: 15840177 DOI: 10.1186/1471-2288-5-13]

14 **Higgins JP,** Green S. The Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 ed, 2011

15 **Harbour R**, Miller J. A new system for grading recommendations in evidence based guidelines. *BMJ* 2001; **323**: 334-336 [PMID: 11498496]

16 **Higgins JP**, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557-560 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]

17 **Braga M**, Frasson M, Vignali A, Zuliani W, Capretti G, Di Carlo V. Laparoscopic resection in rectal cancer patients: outcome and cost-benefit analysis. *Dis Colon Rectum* 2007; **50**: 464-471 [PMID: 17195085 DOI: 10.1007/s10350-006-0798-5]

18 **Liu FL**, Lin JJ, Ye F, Teng LS. Hand-assisted laparoscopic surgery versus the open approach in curative resection of rectal cancer. *J Int Med Res* 2010; **38**: 916-922 [PMID: 20819427]

19 **Lujan J**, Valero G, Hernandez Q, Sanchez A, Frutos MD, Parrilla P. Randomized clinical trial comparing laparoscopic and open surgery in patients with rectal cancer. *Br J Surg* 2009; **96**: 982-989 [PMID: 19644973 DOI: 10.1002/bjs.6662]

20 **Ng SS**, Lee JF, Yiu RY, Li JC, Hon SS, Mak TW, Ngo DK, Leung WW, Leung KL. Laparoscopic-assisted versus open total mesorectal excision with anal sphincter preservation for mid and low rectal cancer: a prospective, randomized trial. *Surg Endosc* 2014; **28**: 297-306 [PMID: 24013470 DOI: 10.1007/s00464-013-3187-x]

21 **Ng SS**, Leung KL, Lee JF, Yiu RY, Li JC, Hon SS. Long-term morbidity and oncologic outcomes of laparoscopic-assisted anterior resection for upper rectal cancer: ten-year results of a prospective, randomized trial. *Dis Colon Rectum* 2009; **52**: 558-566 [PMID: 19404053 DOI: 10.1007/DCR.0b013e31819ec20c]

22 **Ng SS**, Leung KL, Lee JF, Yiu RY, Li JC, Teoh AY, Leung WW. Laparoscopic-assisted versus open abdominoperineal resection for low rectal cancer: a prospective randomized trial. *Ann Surg Oncol* 2008; **15**: 2418-2425 [PMID: 18392659 DOI: 10.1245/s10434-008-9895-0]

23 **Zhou ZG**, Hu M, Li Y, Lei WZ, Yu YY, Cheng Z, Li L, Shu Y, Wang TC. Laparoscopic versus open total mesorectal excision with anal sphincter preservation for low rectal cancer. *Surg Endosc* 2004; **18**: 1211-1215 [PMID: 15457380 DOI: 10.1007/s00464-003-9170-1]

24 **Liang X**, Hou S, Liu H, Li Y, Jiang B, Bai W, Li G, Wang W, Feng Y, Guo J. Effectiveness and safety of laparoscopic resection versus open surgery in patients with rectal cancer: a randomized, controlled trial from China. *J Laparoendosc Adv Surg Tech A* 2011; **21**: 381-385 [PMID: 21395453 DOI: 10.1089/lap.2010.0059]

25 **Araujo SE**, da Silva eSousa AH Jr, de Campos FG, Habr-Gama A, Dumarco RB, Caravatto PP, Nahas SC, da Silva J, Kiss DR, Gama-Rodrigues JJ. Conventional approach x laparoscopic abdominoperineal resection for rectal cancer treatment after neoadjuvant chemoradiation: results of a prospective randomized trial. *Rev Hosp Clin Fac Med Sao Paulo* 2003; **58**: 133-140 [PMID: 12894309]

26 **Guillou PJ**, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, Heath RM, Brown JM; MRC CLASICC trial group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *Lancet* 2005; **365**: 1718-1726 [PMID: 15894098 DOI: 10.1016/S0140-6736(05)66545-2]

27 **Arezzo A**, Passera R, Scozzari G, Verra M, Morino M. Laparoscopy for rectal cancer reduces short-term mortality and morbidity: results of a systematic review and meta-analysis. *Surg Endosc* 2013; **27**: 1485-1502 [PMID: 23183871 DOI: 10.1007/s00464-012-2649-x]

28 **Zhao JK**, Chen NZ, Zheng JB, He S, Sun XJ. Laparoscopic versus open surgery for rectal cancer: Results of a systematic review and meta-analysis on clinical efficacy. *Mol Clin Oncol* 2014; **2**: 1097-1102 [PMID: 25279204 DOI: 10.3892/mco.2014.345]

29 **Vennix S**, Pelzers L, Bouvy N, Beets GL, Pierie JP, Wiggers T, Breukink S. Laparoscopic versus open total mesorectal excision for rectal cancer. *Cochrane Database Syst Rev* 2014; **(4)**: CD005200 [PMID: 24737031 DOI: 10.1002/14651858.CD005200.pub3]

30 **Lujan J**, Valero G, Biondo S, Espin E, Parrilla P, Ortiz H. Laparoscopic versus open surgery for rectal cancer: results of a prospective multicentre analysis of 4,970 patients. *Surg Endosc* 2013; **27**: 295-302 [PMID: 22736289 DOI: 10.1007/s00464-012-2444-8]

31 **Borenstein M,** Hedges LV, Higgins JPT, Rothstein RH. Introduction to Meta-Analysis, 2009

32 **Higgins JP,** Green S. Cochrane Handbook for Systematic Review of Intervention. West Sussex PO19 8SQ, England: Wiley-Blackwell, 2008

33 **Zhao D**, Li Y, Wang S, Huang Z. Laparoscopic versus open surgery for rectal cancer: a meta-analysis of 3-year follow-up outcomes. *Int J Colorectal Dis* 2016; **31**: 805-811 [PMID: 26847617 DOI: 10.1007/s00384-016-2506-9]

34 **Okamura R**, Hida K, Hasegawa S, Sakai Y, Hamada M, Yasui M, Hinoi T, Watanabe M; Japan Society of Laparoscopic Colorectal Surgery. Impact of intraoperative blood loss on morbidity and survival after radical surgery for colorectal cancer patients aged 80 years or older. *Int J Colorectal Dis* 2016; **31**: 327-334 [PMID: 26412248 DOI: 10.1007/s00384-015-2405-5]

35 **Egenvall M**, Mörner M, Påhlman L, Gunnarsson U. Degree of blood loss during surgery for rectal cancer: a population-based epidemiologic study of surgical complications and survival. *Colorectal Dis* 2014; **16**: 696-702 [PMID: 24720780 DOI: 10.1111/codi.12630]

36 **Mahid SS**, Hornung CA, Minor KS, Turina M, Galandiuk S. Systematic reviews and meta-analysis for the surgeon scientist. *Br J Surg* 2006; **93**: 1315-1324 [PMID: 17058324 DOI: 10.1002/bjs.5596]

37 **Horisberger K**, Hofheinz RD, Palma P, Volkert AK, Rothenhoefer S, Wenz F, Hochhaus A, Post S, Willeke F. Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity? *Int J Colorectal Dis* 2008; **23**: 257-264 [PMID: 18071720 DOI: 10.1007/s00384-007-0408-6]

38 **Duldulao MP**, Lee W, Le M, Wiatrek R, Nelson RA, Chen Z, Li W, Kim J, Garcia-Aguilar J. Surgical complications and pathologic complete response after neoadjuvant chemoradiation in locally advanced rectal cancer. *Am Surg* 2011; **77**: 1281-1285 [PMID: 22127070]

39 **Maggiori L**, Bretagnol F, Aslam MI, Guedj N, Zappa M, Ferron M, Panis Y. Does pathologic response of rectal cancer influence postoperative morbidity after neoadjuvant radiochemotherapy and total mesorectal excision? *Surgery* 2014; **155**: 468-475 [PMID: 24439750 DOI: 10.1016/j.surg.2013.10.020]

40 **Landi F**, Espín E, Rodrigues V, Vallribera F, Martinez A, Charpy C, Brunetti F, Azoulay D, de'Angelis N. Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy. *Int J Colorectal Dis* 2017; **32**: 255-264 [PMID: 27757541 DOI: 10.1007/s00384-016-2685-4]

41 **de'Angelis N**, Landi F, Vitali GC, Memeo R, Martínez-Pérez A, Solis A, Assalino M, Vallribera F, Mercoli HA, Marescaux J, Mutter D, Ris F, Espin E, Brunetti F. Multicentre propensity score-matched analysis of laparoscopic versus open surgery for T4 rectal cancer. *Surg Endosc* 2017; **31**: 3106-3121 [PMID: 27826780 DOI: 10.1007/s00464-016-5332-9]

42 **de'Angelis N**, Portigliotti L, Brunetti F. Robot-assisted rectal cancer surgery deserves a fair trial. *Colorectal Dis* 2015; **17**: 824-825 [PMID: 26132357 DOI: 10.1111/codi.13062]

43 **de'Angelis N**, Portigliotti L, Azoulay D, Brunetti F. Transanal total mesorectal excision for rectal cancer: a single center experience and systematic review of the literature. *Langenbecks Arch Surg* 2015; **400**: 945-959 [PMID: 26497544 DOI: 10.1007/s00423-015-1350-7]

44 **Penna M**, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, Moran B, Hanna GB, Mortensen NJ, Tekkis PP; TaTME Registry Collaborative. Transanal Total Mesorectal Excision: International Registry Results of the First 720 Cases. *Ann Surg* 2017; **266**: 111-117 [PMID: 27735827 DOI: 10.1097/SLA.0000000000001948]

45 **Burke JP**, Martin-Perez B, Khan A, Nassif G, de Beche-Adams T, Larach SW, Albert MR, Atallah S. Transanal total mesorectal excision for rectal cancer: early outcomes in 50 consecutive patients. *Colorectal Dis* 2016; **18**: 570-577 [PMID: 26749148 DOI: 10.1111/codi.13263]

**P-Reviewer:** Aytac E, De Nardi P, García-Flórez LJ, Seow-Choen F

**S-Editor:** Gong ZM **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** France

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

## Identification

## Screening

## Eligibility

Studies included in the qualitative and quantitative syntesis (*n* = 14)

Articles assessed for eligibility on full-text (*n* = 369)

Records excluded:

- Non-relevant study design

- Not pertinent to review question

- Learning curve (*n* = 355)

## Included

Records excluded because non-pertinent to the review question (*n* = 5836)


Selected articles (*n* = 14)

Articles screened on title and abstract


Records identified through database searching on Cochrane, PubMed, EMBASE, Scopus   
(after removing duplicates) (*n* = 6205)

**Figure 1 Flowchart of the literature search and study selection process according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines.**


a




b




c



D

**

e



**Figure 2 Forest plots of short-term outcomes showing significant differences between laparoscopic rectal resection and open rectal resection.** A: Operative time; B: Estimated blood loss; C: Incision length; D: Length of hospital stay; E: Bowel recovery.

**Table 1 Summary of the included randomized clinical trials**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Number of centers involved (country) in the RCT and in the study period** | **Inclusion criteria** | **Exclusion criteria** | ***n*** | **Surgical approach** | | | **Types of procedure** | | **Preoperative treatment** | |
| **Lap (*n*)** | **Conversion rate (%)** | **Open (*n*)** | **Lap (%)** | **Open (%)** | **Lap (%)** | **Open (%)** |
| Fleshman *et al*[5], 2015 | 35 (United States-Canada)  Oct 2008-Sep 2013 | S. II-III rectal cancer ≤ 12 cm from AV | 1-11 | 462 | 240 | 11.25 | 222 | LAR (74.6) APR (24.2) H (0.4) TPC (0.8) | AR (76.1) APR (21.2) TPC 6 (2.7) | CRT (95) RT (3.3) CT (1.7) | CRT (91.2) RT (5.5) CT (3.4) |
| Stevenson *et al*[6], 2015 | 24 (Australia-N. Zeal)  Mar 2010-Nov 2014 | T1-3 rectal cancer ≤ 15 cm from AV | 1,2,4,7, 10, 12,13 | 473 | 238 | 8.82 | 235 | LAR (89)  APR (11) | AR (90)  APR (10) | RT (50) | RT (49) |
| Ng *et al*[20], 2014 | 1 (Hong Kong)  Aug 2001-Aug2007 | Rectal cancer low margin 5-12 cm AV | 13,16,17, 23,24,25 | 80 | 40 | 7.50 | 40 | LAR (100) | AR (100) | (0) | (0) |
| van der Pas *et al*[3], 2013 | 30 (Europe- Canada-South Korea)  Jan 2004-May 2010 | T1-3 rectal cancer ≤ 15 cm from AV | 1,2,9,  10,13-22 | 1044 | 699 | 16.40 | 345 | LAR (70)  APR (29) U (1) | AR (77)  APR (23) | RT (59)  CT (32) | RT (58)  CT (34) |
| Liang *et al*[24], 2011 | 1 (China)  May 2004-April 2008 | Rectal cancer | 16,25,26,  31,34,35 | 343 | 169 | 0.59 | 174 | LAR (50.9)  APR (49.1) | AR (59.8)  APR (40.2) | (0) | (0) |
| Kang *et al*[4], 2010 | 3 (South Korea)  Apr 2006-Aug 2009 | T1-3 rectal cancer ≤ 9 cm from AV | 1,5,10,13,16,21,23,26 | 340 | 170 | 1.18 | 170 | LAR (85.9)  APR (14.1) | AR (88.8)  APR (11.2) | CRT (100) | CRT (100) |
| Liu *et al*[18], 2010 | 1 (China)  Feb 2005-Oct 2008 | Rectal cancer | 16,17,23 | 186 | 98 | 0 | 88 | 1LAR (69.4) H 14 (14.3) APR (12.2) O 4 (4.1) | AR (67) H (12.5)  APR (15.9) O 4 (4.5) | (0) | (0) |
| Ng *et al*[21], 2009 | 1 (Hong Kong)  Sep 1993-Oct 2002 | Rectal cancer low margin 12-15 cm AV | 1,16,23,24,27,28 | 153 | 76 | 30.26 | 77 | LAR (100) | AR (100) | (0) | (0) |
| Luján *et al*[19], 2009 | 1 (Spain)  Jan 2002-Feb 2007 | Mid or low rectal cancer | 1,13,18,29 | 204 | 101 | 7.92 | 103 | LAR 77 (76.2)  APR 24 (23.8) | AR (78.6)  APR (21.4) | CRT (72.3) | CRT (74.8) |
| Ng *et al*[22], 2008 | 1 (Hong Kong)  Sep1994-Feb 2005 | Low rectal cancer | 13,16,  23,24,30 | 99 | 51 | 9.80 | 48 | APR (100) | APR (100) | (0) | (0) |
| Braga *et al*[17], 2007 | 1 (Italy)  Period n.a. | Rectal cancer | 1,2,10,13,31 | 168 | 83 | 7.23 | 85 | LAR (91.6)  APR (8.4) | AR (87)  APR (13) | CRT (16.9) | CRT (14.1) |
| Guillou *et al*[26], 2005 | 27 (United Kingdom)  Jul 1996 - Jul 2002 | Colorectal cancer (excl. transverse) | 11,16,17,  21, 32,33 | 381 | 253 | 33.88 | 128 | AR 167 (66) APR (25) S (3) LH (2) O (3) U (1) | AR (62) RC 1 (1) S 7 (5) APR (27) O 4 (3) U (2) | na | na |
| Zhou *et al*[23], 2004 | 1 (China)  Jun 2001 - Sep 2002 | 1.5 cm above AV to peritoneal reflection | 1,13,29 | 171[24] | 82 | na | 89 | LAR (100) | AR (100) | (0) | (0) |
| Araujo *et al*[25], 2003 | 1 (Brazil)  Sep 1997-Sep 2000 | Low rectal cancer not responding RCT | 1 | 28 | 13 | 0 | 15 | APR (100) | APR (100) | CRT (100) | CRT (100) |

1Hand-assisted procedures. Exclusion criteria: (1)Tumors other thanhistologically confirmed adenocarcinoma, (2) Age > 18 years, (3) body mass index (BMI) > 34, (4) Eastern Cooperative Oncology Group (ECOG) performance score ≥ 3, (5) Not receiving neoadjuvant chemoradiotherapy/radiotherapy, (6) Operation not performed between 4-12 wk of the final radiation treatment, (7) History of invasive pelvic malignancy within 5 years, (8) psychiatric or addictive disorders that affected compliance with the protocol, (9) American Society of Anesthesiologists (ASA) classification IV or V, (10) Severe systemic disease, (11) Conditions that limited the success of the laparoscopic resection, (12) Life expectancy of at least 12 weeks, (13) T4 tumors/involved CRM pretreatment, (14) T1 tumor treated with local transanal excision, (15) History of other malignancy except basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri, (16) Signs of acute intestinal obstruction, (17) Need for synchronous colorectal surgery, (18) Familial adenomatous polyposis coli/hereditary non-polyposis, (19) Colorectal cancer, (20) Active Crohn’s disease/ulcerative colitis, (21) Pregnancy, (22) T3 rectal cancer within 2 mm from the endopelvic fascia, (23) Tumor perforation, (24) Tumor larger than 6 cm, (25) Neoadjuvant chemoradiotherapy, (26) Distant metastasis, (27) Distal tumor that needed an anastomosis within 5 cm of the dentate line, (28) Previous abdominal operations near the region of the colorectal operation, (29) Emergency surgery, (30) recurrent disease, (31) ongoing infection/ plasma neutrophil level < 2 × 109/l, (32) Associated gastrointestinal disease that needed surgical intervention, (33) Malignant disease in the past 5 years, (34) BMI > 30 kg/m2, (35) previous abdominal surgery. AV: Anal verge; Lap: laparoscopy; LAR: Laparoscopic anterior resection; AR: Anterior resection; APR: Abdominoperineal amputation; TPC: Total Proctocolectomy; H: Hartmann; S: Sigmoidectomy; LH: Left Hemicolectomy; RC: Right colectomy; O: Other; U: Unknown; CRT: Chemoradiotherapy; RT: Radiotherapy; CT: Chemotherapy.

**Table 2 Results of the meta-analyses comparing laparoscopic rectal resection *vs* open rectal resection**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Outcome variables** | **Number of studies (Number of patients)** | **RR or MD** | **95%CI (Low; High)** | ***p* value** | **Heterogeneity, *I2*(*p* value)** | **Sensitivity analysis by including the largest multi-centric RCTs** | | | | |
| **Number of studies (Number of patients)** | **RR or MD** | **95%CI (Low; High)** | ***p* value** | **Heterogeneity, *I2*(*p* value)** |
| **Intraoperative outcomes** | | | | | | | | | | |
| Operative time | 12 (3723) | 36.67 | 27.22; 46.11 | <0.00001 | 89% (< 0.00001) | 4 (2319) | 41.18 | 24.88; 57.48 | < 0.00001 | 85% (0.0002) |
| Intraoperative morbidity | 4 (1909) | 0.97 | 0.74; 1.27 | 0.82 | 8% (0.35) | 2 (1500) | 1.02 | 0.60; 1.72 | 0.94 | 61% (0.11) |
| Estimated blood loss | 11 (3380) | -88.80 | -117.25; -60.34 | < 0.00001 | 83% (< 0.00001) | 4 (2319) | -82.10 | -158.87; -5.34 | 0.04 | 94% (< 0.00001) |
| Incision length | 5 (1629) | -11.17 | -13.88; -8.47 | < 0.00001 | 99% (< 0.00001) | 3 (1275) | -10.51 | -16.16; -4.85 | 0.0003 | 99% (< 0.00001) |
| Ureter injury | 5 (2256) | 1.23 | 0.20; 7.72 | 0.82 | 51% (0.11) | 2 (1500) | 2.59 | 0.66; 10.11 | 0.17 | 0% (0.67) |
| Gastrointestinal injury | 4 (2052) | 1.14 | 0.25; 5.17 | 0.86 | 73% (0.02) | 2 (1500) | 1.05 | 0.13; 8.22 | 0.96 | 86% (0.007) |
| **Postoperative outcomes** | | | | | | | | | | |
| Postoperative morbidity | 12 (3313) | 0.98 | 0.88; 1.09 | 0.75 | 16% (0.3) | 3 (1844) | 1.02 | 0.91; 1.15 | 0.69 | 0% (0.65) |
| Postoperative mortality | 13 (3751) | 0.65 | 0.34; 1.23 | 0.19 | 0% (1) | 4 (2319) | 0.60 | 0.27; 1.33 | 0.21 | 0% (0.89) |
| Length hospital stay | 12 (3738) | -1.71 | -2.84; -0.58 | 0.003 | 90% (< 0.00001) | 4 (2296) | -0.25 | -0.90; 0.39 | 0.44 | 52% (0.10) |
| Anastomotic leak | 9 (2253) | 0.97 | 0.69; 1.34 | 0.84 | 0% (0.6) | 3 (1351) | 1.19 | 0.79; 1.80 | 0.41 | 0% (0.53) |
| Reoperation rate | 7 (2468) | 0.93 | 0.64; 1.34 | 0.69 | 3% (0.4) | 3 (1844) | 1.19 | 0.77; 1.86 | 0.43 | 0% (0.42) |
| Ileus | 10 (2930) | 0.77 | 0.55; 1.06 | 0.11 | 0% (0.66) | 3 (1875) | 0.79 | 0.43; 1.44 | 0.44 | 62% (0.07) |
| Bowel recovery | 9 (3149) | -0.68 | -1.00; -0.36 | < 0.0001 | 79% (< 0.00001) | 3 (1922) | -0.59 | -1.24; 0.07 | 0.08 | 87% (0.0005) |
| Wound infection | 10 (2684) | 0.81 | 0.61; 1.09 | 0.16 | 0% (0.5) | 1 (1042) | 0.82 | 0.43;1.47 | 0.50 | na |
| Chest infection | 7 (1252) | 1.55 | 0.82; 2.93 | 0.17 | 0% (0.61) | 0 (0) | - | - | - | - |
| Urinary infection | 7 (1075) | 0.89 | 0.50; 1.57 | 0.68 | 15% (0.32) | 0 (0) | - | - | - | - |

RR: risk ratios; MD: mean difference; CI: confidence interval; na: not applicable.